Drug intelligence / Profile preview

ALKS 7290

Development stage: Phase 2
Lead developer: Alkermes
Modality: Small Molecules
Administration: Oral

Overview

**ALKS 7290** is an investigational, small molecule agonist of the orexin receptor type 2 (OX2R). It is being developed by Alkermes for the treatment of central nervous system (CNS) disorders, such as central disorders of hypersomnolence, including narcolepsy and potentially other psychiatric and neurological conditions. ALKS 7290 is currently in phase 1 clinical development, with ongoing evaluation in healthy volunteers. The drug is part of Alkermes' orexin-targeting neuroscience program, which aims to deliver novel and differentiated new treatments for CNS disorders by modulating the orexin neuropeptide system implicated in maintaining wakefulness and regulating arousal[1][3][5][6].

Other names: ALKS 7290ALKS7290ALKS-7290

Targets

HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on ALKS 7290.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALKS 7290.

Explore the full profile